Drugs / BHV-1530
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06874335 | Mar 2025 → Mar 2029 expected | cancer | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-1530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06874335 ↗ |
| Route | Intravenous | “BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle” NCT06874335 ↗ |